A Clinician’s Handbook for Childhood & Adult Immunizations in Georgia

# Meningococcal Vaccination Recommendations

**This table covers routine vaccination of preteens and teens, as well as catch-up vaccination of teens and young adults.**

Age of Patient | Vaccination History | Recommended MenACWY Schedule |
---|---|---|

Age 11 through 12 years | None | Give dose #1 of MenACWY. |

Age 13 through 15 years | None | Give catch-up dose #1 of MenACWY. |

Age 16 years | 1 prior dose | Give dose #2 of MenACWY. |

Age 16 through 18 years | None | Give 1 dose of MenACWY. |

Age 16 through 18 years | 1 prior dose when younger than 16 yrs | Give dose #2 of MenACWY. |

Age 19 through 21 years | None, or 1 prior dose when younger than 16 yrs | Consider giving 1 dose of MenACWY. |

First year college students living in residence halls | None, or 1 prior dose when younger than 16 yrs, or 1 prior dose since 16th birthday, but more than 5 yrs previously | Give 1 dose of MenACWY. |

## Risk-based Recommendations for Persons with

Underlying Medical Conditions or Other Risk Factors

**Travelers to or residents of countries where meningococcal disease is hyperendemic or epidemic, people present during outbreaks caused by a vaccine serogroup,(2)**^{ }**and other people with prolonged increased risk for exposure (e.g., microbiologists routinely working with ***Neisseria meningitidis*).

*Neisseria meningitidis*).

Targeted Group by Age/or Risk Factor | Primary Dose(s)1 | Booster Dose(s)1 |
---|---|---|

For age 2 through 6 months | Give 3 doses of Menveo, 8 weeks apart, and a 4th dose at age 12–18 months. If possible, vaccination should begin at age 2 months. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains.(4) If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |

For age 7 through 23 months who have not initiated a series of MenACWY | If age 7–8 months, initiate 2-dose series of Menveo(3) or, if age 9–23 months, give either Menveo or Menactra.(4) Separate the 2 doses by at least 12 weeks. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains.(4) If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |

For age 2 years and older | Give 1 dose of any MenACWY vaccine.(4) | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains.(4) If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |

**People with persistent complement component deficiencies**

Targeted Group by Age/or Risk Factor | Primary Dose(s)1 | Booster Dose(s)1 |
---|---|---|

For age 2 through 6 months | Give 3 doses of Menveo, 8 weeks apart, and a 4th dose at age 12–18 months. If possible, vaccination should begin at age 2 months. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |

For age 7 through 23 months who have not initiated a series of MenACWY | If age 7–8 months, initiate 2-dose series of Menveo or, if age 9–23 months, give either Menveo or Menactra. Separate the 2 doses by at least 12 weeks. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |

For ages 2 years and older | Give 2 doses of MenACWY (any vaccine), 8 weeks apart.4,7 | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |

**People with HIV infection or functional or anatomic asplenia** **(including sickle cell disease)**

Targeted Group by Age/or Risk Factor | Primary Dose(s)1 | Booster Dose(s)1 |
---|---|---|

For age 2 through 6 months | Give 3 doses of Menveo, 8 weeks apart, and a 4th dose at age 12–18 months. If possible vaccination should begin at age 2 months. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter. |

For age 7 through 23 months who have not initiated a series of MenACWY-CRM | Give 2 doses of Menveo. Separate the 2 doses by at least 12 weeks. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter. |

For ages 2 years and older | Give 2 doses of MenACWY (any vaccine), 8 weeks apart. If using Menactra, give dose #1 at least 4 weeks after final dose of PCVl3 | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter. |

### Footnotes:

- If available, use the same vaccine product for all doses in the series given to infants, including the booster doses.
- Seek advice of local public health authorities to determine if vaccination is recommended.
- If initiating vaccination with Menveo in a child age 7 through 23 months, dose 2 should be given no younger than age 12 months.

4. If Menactra is to be administered to a child with increased risk for meningococcal disease, it should be given either before, at the same visit, or at least 6 months after Menveo and MenQuadfi can be given at any time before or after DTaP.

5. If child age 7 through 23 months will enter an endemic area in less than 3 months, give doses as close as 2 months apart.

6. Persistent deficiency of complement components C3, CS- C , properdin, factor D, or factor H caused by an immune system disorder or by taking a complement inhibitor (Soliris [eculizumab] or Ultomiris [ravulizumab]).

7. If the person has a history of l dose of MenACWY at the time of diagnosis with a high-risk condition for which a 2-dose pri- mary series is recommended, give dose 2, then boost every 5 years as long as risk remains.